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Abstract
Background Lymph node status is one of the decisive
prognostic factors in breast cancer. Chemotherapy targeting
regional lymphatic tissues has emerged as a promising therapy
for the treatment of malignancies with a high tendency to
disseminate lymphatically. The present study determined the
drug concentrations in axillary lymph nodes after lymphatic
chemotherapy (LC) in patients with breast cancer and
compared the results with those receiving intravenous
chemotherapy (VC) to investigate whether LC could improve the
accumulation of anticancer drug in regional lymph nodes.
Methods Sixty patients with breast carcinoma confirmed by
preoperative puncture-biopsy were divided into two groups at
random. The LC group (n  = 30) received a subcutaneous
injection of 4 ml of carboplatin-activated carbon suspension,
containing 20 mg of carboplatin, adjacent to the primary tumour.
The VC group (n = 30) received an intravenous administration
of an equal dose of aqueous carboplatin. At 1, 12, 24, 36 and
48 hours after administration, modified radical mammectomies
were performed on 12 patients at each time point, with 6 from
each group. Axillary lymph nodes were removed for pathological
examination. The platinum concentrations in nodes were
determined by Zeeman atomic absorption spectrometry.
Results A total of 275 axillary lymph nodes were resected, with
154 in the LC group and 121 in the VC group. Of the 275 lymph
nodes, 136 (49.5%) from 23 patients (38.3%) had
histopathologically detected metastases. At 1, 12, 24, 36 and
48 hours after injection, the carboplatin concentrations in the LC
group were 11.82 ± 3.50, 23.58 ± 7.34, 18.22 ± 4.93, 16.70
± 5.15 and 14.62 ± 4.29 µg/g (means ± SD), respectively,
whereas those in the VC group were 0.06 ± 0.02, 0.11 ± 0.05,
0.10 ± 0.02, 0.05 ± 0.02 and 0 µg/g, respectively. Significant
differences were found in each corresponding comparison (P <
0.001). Lymph node metastasis was uncorrelated with drug
concentration (P > 0.05).
Conclusion LC can effectively and continuously improve the
drug concentrations in axillary lymph nodes in patients with
breast cancer, in comparison with VC.
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Introduction
Regional lymph nodes are a common site for the postoper-
ative relapse of advanced breast carcinoma. To improve the
prognosis, axillary lymph nodes are routinely resected in
radical mammectomy. However, there are several paths
through which lymph drains from the breast to adjacent tis-
sues, as shown in recent studies on sentinel lymph node
[1,2]. Radical mammectomy fails in excising lymph nodes
located in the mediastinum, internal mammary or hepatic
portal. A similar problem can also be found in cancers of
the digestive tract, which also tend to metastasize
lymphatically.
During recent years, some gastroenterologists have admin-
istered preoperative chemotherapy targeting regional
lymph nodes for gastric, oesophageal, rectal or peritoneal
cancer by using special drug carriers such as activated car-
bon or liposomes [3-6]. Their results showed promise for
the prevention of metastasis and recurrence after radical
resection. The new method for the treatment of likely
metastasis to regional lymphatic tissue is called lymphatic
chemotherapy (LC) or medicinal lymph node dissection. In
the present study we administered carboplatin-activated
carbon suspension (CP-CH) to patients with breast carci-
noma and determined the platinum concentrations in
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axillary lymph nodes at different intervals. The results were
compared with those obtained after intravenous chemo-
therapy (VC) with an equal dose of carboplatin solution
(CP-Sol) to discover whether LC could effectively improve
the anticancer drug accumulation in regional lymphatic
tissues.
Materials and methods
Patients and study design
From June 2002 to August 2003 a total of 60 female
patients with breast carcinoma confirmed by preoperative
puncture-biopsy were enrolled in this study. The ages of
patients ranged from 35 to 71 years (mean 49.2 years). The
pathological diagnoses were as follows: ductal (n = 28),
lobular (n = 18), medullary (n = 6), mucinous (n = 4), tubu-
lar (n = 3) and papillary (n = 1) carcinoma, respectively.
According to the TNM classification (AJCC Cancer Stag-
ing Manual, 6th edition, 2002), 11 patients fell into the T1
category, 38 into T2, 8 into T3 and 3 into T4. Axillary lymph
node metastases were present in 23 patients; of these, 17
were classified as N1, 5 as N2 and 1 as N3. Distant metas-
tases occurred in four patients. Clinical grades consisted of
grade I (n = 9), grade II (n = 40), grade III (n = 7), and grade
IV (n = 4). Locations of tumours were as follows: subnipple
(n = 5), outer-upper (n = 21), outer-lower (n = 14), inner-
upper (n = 11) and inner-lower (n = 9) field. The inclusion
criteria included the following: World Health Organization
status of 0 or 1, without previous chemotherapy or radiation
therapy, white blood cell count greater than 4000/µl and
platelet count greater than 100,000/µl, no abnormality of
cardiac, renal or liver function. The patients who met these
criteria were divided into two groups in accordance with a
prospectively generated randomization schedule, with 30
patients in each group, to receive either LC or VC as pre-
operative adjuvant treatment. The study protocol was
approved by our institutional review board as being in
accordance with the Declaration of Helsinki. Informed con-
sent was obtained from every patient before enrolment.
Preparation of CP-CH
Activated carbon granules (CHR-30) were ground in a ball-
mill and sifted with a 100-mesh sieve. The 100-mesh pass-
ing fraction, 81% of which was smaller than 40 µm, was
used for this preparation as activated carbon particles.
After the moisture had been removed from the activated
carbon particles by dry heating at 120°C for 2 hours, 375
mg of activated carbon particles was sealed in a glass tube,
which was sterilized under two atmospheres of pressure
for 10 minutes and stored in a refrigerator. Just before use,
100 mg of carboplatin dissolved in 20 ml of normal saline
was added to the activated carbon particles. The mixture
was shaken for 10 minutes to allow sufficient adsorption of
carboplatin on the activated carbon particles, resulting in
CP-CH [6].
Determinations of tissue platinum
Patients in the LC group received a subcutaneous injection
of 4 ml of CP-CH, containing 20 mg of carboplatin, adja-
cent to the primary tumour. The VC group received an intra-
venous injection of 4 ml of CP-Sol containing 20 mg of
carboplatin. Modified radical mammectomies were per-
formed 1, 12, 24, 36 and 48 hours later on 12 patients,
with 6 from each group each time. Axillary lymph nodes
were excised entirely, one of which was picked at random
and split into two parts: one part was sent for platinum
examination, and the remaining part and the rest of the
lymph nodes were sent for histopathological observation.
The lymph node for platinum examination was cut to a frag-
ment weighing 200 mg and placed in a 5 ml screw-capped
tube. The fragment was left to stand overnight with 4 ml of
10% hydrochloric acid and 70% nitric acid (1:4, by vol-
ume). The following day, tissue was digested for 2 hours at
90°C in an electric frying pan positioned in a fume hood.
The solubilized tissue was dried and mixed with 0.5 ml of
Milli-Q water. The solution was subjected to graphite-fur-
nace Zeeman atomic absorption spectrometry. Platinum
analysis was performed as described previously [7]. The
concentration of carboplatin was determined by multiplying
the concentration of platinum by 1.903.
Statistical analysis
Concentrations are shown as means ± SD. Results were
tested for significant differences by Fisher's test and Stu-
dent's t-test. P < 0.05 was considered to indicate statistical
significance.
Results
A total of 275 axillary lymph nodes were resected during
operations, with 154 in the LC group and 121 in the VC
group. Of the 275 lymph nodes, 146 (53.1%) from 23
patients (38.3%) had histopathologically detected metas-
tases. Of these 146 metastasized nodes, 80 were from 13
patients in the LC group and 66 were from 10 patients in
the VC group. No statistical difference in case distribution
was found (P > 0.05) between the two groups.
At 1, 12, 24, 36 and 48 hours after local injection of CP-
CH, the mean carboplatin concentrations in axillary lymph
nodes were 11.82 ± 3.50, 23.58 ± 7.34, 18.22 ± 4.93,
16.70 ± 5.15 and 14.62 ± 4.29 µg/g, respectively,
whereas the concentrations were 0.06 ± 0.02, 0.11 ±
0.05, 0.10 ± 0.02, 0.05 ± 0.02 and 0 µg/g, respectively
after intravenous injection of CP-Sol (Fig. 1). The difference
was significant in each corresponding comparison (P <
0.001).
Among the 60 lymph nodes that were sent for platinum
determination, 19 (31.7%) had histopathologically
detected metastases. Of these 19 nodes, 11 belonged to
the LC group with the mean carboplatin concentration ofAvailable online http://breast-cancer-research.com/content/6/4/R474
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15.48 ± 6.10 µg/g. Of the remaining 41 nodes without
metastasis, 19 were from the LC group with the mean car-
boplatin concentration of 17.24 ± 7.82 µg/g. No significant
difference was found (P > 0.05) between them.
Discussion
Regional lymphatic tissues are often involved in advanced
breast carcinoma. Lymph nodes adjacent to the primary
tumour are susceptible to metastases, which usually lead to
recurrences and distant metastases after curative resec-
tion. However, the traditional therapies for breast carci-
noma are not satisfactory in solving this problem.
Mediastinal, parasternal or parahepatic lymph nodes, which
are likely to be affected by metastases because they
receive lymph drainage from breast tissues, cannot be
resected in radical mammectomy. Even lymph nodes and
lymphatic vessels located in the axilla can rarely be dis-
sected entirely. Furthermore, the destruction of lymphatic
tissues during operation can bring about the dissemination
of tumour cells in the operating field. Radiotherapy cannot
effectively improve the result either, because of the limita-
tion of the radiation field. VC supplies an extensive distribu-
tion of anticancer drugs. Unfortunately, high-dose
anticancer drugs are often associated with acute toxicity,
such as myelosuppression and immunosuppression, as
well as with cumulative cardiotoxicity. As a result, only lim-
ited quantities of drugs are thereby distributed to lymphatic
tissues.
LC, as a potential method for solving this problem, has
been proved to have preventive effects on lymphatic metas-
tases of gastroenteric cancers [3-6]. In the process, acti-
vated carbon and liposomes have been most extensively
explored for their excellent characteristic of transferring
anticancer drugs to regional lymphatic tissues after local
administration [8].
We used activated carbon to deliver carboplatin in the
present study. Activated carbon particles have numerous
micropores that can adsorb large amounts of anticancer
agents, such as mitomycin C, methotrexate, peplomycin or
carboplatin. Once injected into the connective system, they
are taken up selectively by lymphatic vessels and delivered
to neighbouring lymph nodes. The lymph nodes then turn
black, which simplifies their identification during radical
lymphadenectomy [9].
Our results confirmed that subcutaneous injection of CP-
CH adjacent to the primary tumour could provide a specific
and continuous delivery of carboplatin to axillary lymph
nodes. Carboplatin concentrations after regional adminis-
tration of CP-CH were markedly higher than those after
intravenous administration of CP-Sol at each sampling
time. The mean drug levels at 1, 12, 24 and 36 hours after
administration of CP-CH were 197, 214, 182 and 334
times higher than the corresponding drug levels after
administration of CP-Sol.
On the other hand, drug determination at different sampling
times indicated that CP-CH evidently slowed down the
clearance of carboplatin in lymph nodes. It is well known
that both prolonging the duration and elevating the concen-
tration of carboplatin improves its anticancer efficacy [10].
The mean carboplatin concentration of lymph nodes with-
out metastasis (17.24 µg/g) was slightly higher than that of
lymph nodes with metastasis (15.48 µg/g), but the differ-
ence was not statistically significant. The result indicated
that metastatic tumour cells in nodes exerted little influence
on the accumulation of CP-CH at lymph nodes.
No haematological or non-haematological toxicities were
detected in this experiment owing to the small dose of car-
boplatin used on its own. No evidence of local toxicity such
as drug allergy, ulceration or erosion of skin was observed
from CP-CH injection to operation, except that there were
some carbon particles and inflammatory cells gathering at
the injection sites, as detected pathologically, suggesting
that the clinical application of CP-CH could be safe.
Conclusions
In conclusion, our study shows that LC could effectively
and continuously improve concentration of anticancer drug
in regional lymph nodes adjacent to the primary tumour in
comparison with intravenous administration. Further inves-
tigations are warranted to reveal whether preoperative LC
is useful in preventing the recurrence of cancer and in
improving survival after mammectomy.
Figure 1
Mean carboplatin concentrations in axillary lymph nodes at different  times after administration Mean carboplatin concentrations in axillary lymph nodes at different 
times after administration. Filled circles represent concentrations after 
administration of carboplatin-activated carbon suspension; open circles 
represent concentrations after administration of carboplatin solution.
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